Security key
20454B104
Compass Therapeutics, Inc. - COMMON STOCK (CMPX)
CUSIP: 20454B104
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 108,444,414
- Total 13F value
- $206,047,938
- Share change
- +7,077,823
- Put/Call ratio
- 130%
- SEC-reported price per share
- $1.90
- Number of holders
- 107
- Value change
- +$13,824,994
- Number of buys
- 55
- Number of sells
- 38
- Shares outstanding
- 180,975,509
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
107
Top holders
10
CMPX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Compass Therapeutics, Inc. SEC filings
Compass Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 20454B104
Recent filing periods:
Ownership snapshot
Top reported holders of CMPX - Compass Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ADAGE CAPITAL PARTNERS GP...
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 4.4%
13D/G row: ADAGE CAPITAL PARTNERS GP, L.L.C.
Showing 1-6 of 15 holder rows.
Quick read
ADAGE CAPITAL PARTNERS GP, L.L.C. leads the comparable SEC ownership view at 4.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ADAGE CAPITAL PARTNERS GP, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
ADAGE CAPITAL PARTNERS GP, L.L.C.
4.4%
ORBIMED ADVISORS LLC
12%
Blackstone Inc.
5.5%
MPM BioImpact LLC
4.7%
Enavate Sciences GP, LLC
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13D/G
13F
Adage Capital Management, L.P. · Company
|
4.4%
|
$11,629,931
5,994,810 shares
|
$0 | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
12%
|
$32,426,133
22,362,850 shares
|
— | 31 Dec 2024 |
| Blackstone Inc. |
13F
Company
|
5.5%
|
$14,536,469
10,025,151 shares
|
— | 31 Dec 2024 |
| MPM BioImpact LLC |
13F
Company
|
4.7%
|
$12,423,449
8,567,896 shares
|
— | 31 Dec 2024 |
| Enavate Sciences GP, LLC |
13F
Company
|
4.3%
|
$11,292,818
7,788,150 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
3.8%
|
$9,987,043
6,887,615 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
107
Shares
108,444,414
Rows available
107
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
107
Q1 2025 holders
107
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend